Several prospective studies have observed that first-line EGFR-TKI treatment leads to longer progression-free survival in NSCLC patients with such EGFR mutations compared with platinum-based doublet chemotherapy (1–4). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.